Literature DB >> 463773

Polymorphous ventricular tachycardia: clinical features and treatment.

S Sclarovksy, B Strasberg, R F Lewin, J Agmon.   

Abstract

Thirty-four cases of ventricular tachyarrhythmia characterized by polymorphy of the QRS complexes with changing R-R intervals and a heart rate of 150 to 300 beats/min, termed polymorphous ventricular tachycardia, are described. The factors involved in the appearance of this arrhythmia were the administration of antiarrhythmic drugs (quinidine 22 patients, procainamide 5 patients, ajmaline 1 patient), antianginal drugs (prenylamine [Synadrin] 4 patients) and antidepressant drugs (thioridazine 1 patient). Twenty-one patients were treated for premature ventricular complexes, three for chronic recurrent ventricular tachycardia, six for atrial flutter and fibrillation, three for anginal pain and one patient for mental depression. All patients except one had a drug-induced prolonged corrected Q-T interval before the appearance of polymorphous ventricular tachycardia. Most of the patients with this arrhythmia were considered to have severe myocardial disease. Lidocaine and electric cardioversion were administered to all patients, but were effective only in seven patients whose tachycardia occurred in short, single episodes. The most effective treatment (17 patients) was temporary ventricular pacing at rates ranging from 100 to 140 beats/min. Intravenous isoproterenol proved to be successful in another 10 cases. It is concluded that patients with severe myocardial involvement receiving antiarrhythmic drugs for premature ventricular complexes, especially the multiform variety, are at high risk for the development of polymorphous ventricular tachycardia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 463773     DOI: 10.1016/0002-9149(79)90326-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  Torsades de Pointes.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

2.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

3.  Torsades de pointes: arrhythmia, syndrome, or chimera?

Authors:  R N Millar
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

4.  Importance of QT interval in clinical practice.

Authors:  Anand Ambhore; Swee-Guan Teo; Abdul Razakjr Bin Omar; Kian-Keong Poh
Journal:  Singapore Med J       Date:  2014-12       Impact factor: 1.858

5.  "Torsade de pointes" tachycardia. Re-entry or focal activity?

Authors:  C N D'Alnoncourt; W Zierhut; B Blüderitz
Journal:  Br Heart J       Date:  1982-09

Review 6.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

7.  Satalol-induced torsade de pointes.

Authors:  A Kontopoulos; A Filindris; F Manoudis; P Metaxas
Journal:  Postgrad Med J       Date:  1981-05       Impact factor: 2.401

8.  Torsade de pointes.

Authors:  S K Agarwal
Journal:  J Natl Med Assoc       Date:  1981-10       Impact factor: 1.798

9.  Terminology of torsades de pointes.

Authors:  D Tzivoni; A Keren; S Banai; S Stern
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 10.  Torsades de pointes: prevention and therapy.

Authors:  A Keren; D Tzivoni
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.